(Oslo, 14th of April 2026) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarters in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
surgery, announces the Annual General Meeting for the company.
The Annual General Meeting will take place on the 6th of May 2026 at 10.00 and
is held at Medistim's offices at Økernveien 94 in Oslo. Attached are the agenda
for the meeting and the voting form. Shareholders will receive a separate letter
including reference and pin code to register votes. It is possible to give proxy
with and without voting instructions. By using a proxy with voting instructions,
the shareholders will vote on the specific issues without personal attendance.
For further information on the use of proxy and voting, see general information
at the bottom of the notice and enclosed proxy forms.
About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past >15 years. The company is a pioneer within its segment, and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, UK,
Spain, Denmark, Sweden, Japan and Norway, in addition to the about 60
distributors in Europe, Asia, Middle East, Africa, Canada and South America.
For more information, visit the Medistim home page: www.Medistim.com
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act (Verdipapirhandelloven).
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com